Last reviewed · How we verify
Avelumab Injection
At a glance
| Generic name | Avelumab Injection |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors (PHASE1)
- Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma (PHASE2)
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (PHASE2)
- Palbociclib After CDK and Endocrine Therapy (PACE) (PHASE2)
- A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers (PHASE1)
- AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (PHASE1)
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avelumab Injection CI brief — competitive landscape report
- Avelumab Injection updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI